Menarini (MEN1611) is a novel oral PI3Kδ inhibitor that exhibits lower cytotoxic activity than taselisib in a p110δ-driven HER2-positive BC cell model and higher cytotoxic activity than alpelisib in a p110β-driven cellular model [60]. Here, ERBB2 is linked to breast cancer.